FGFR1 Antikörper (C-Term)

Produktnummer ABIN374521

Dieser Ziege Polyklonal Antikörper detektiert spezifisch FGFR1 in WB. Es zeigt Reaktivität gegenüber Proben von Human, Hund und Schimpanse.

Kurzübersicht für FGFR1 Antikörper (C-Term) (ABIN374521)

Target: FGFR1 (Fibroblast Growth Factor Receptor 1 (FGFR1))

Reaktivität: Human, Hund, Schimpanse

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Dieser FGFR1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-FGFR1 Antikörper

Bindungsspezifität: C-Term

Spezifität: This antibody reacts to CD331.

Kreuzreaktivität (Details): Species reactivity (expected):Canine, Bovine.
Species reactivity (tested):Human.

Aufreinigung: Affinity chromatography

Immunogen: Peptide with sequence CLPRHPAQLANGGLKR, from the C Terminus of the protein sequence

Anwendungsinformationen

Applikationshinweise: Peptide ELISA: 1/32000. Western Blot: 0.3 - 1 μg/mL. Immunohistochemistry on paraffin sections: 4 - 6 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0,5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu FGFR1

Target: FGFR1 (Fibroblast Growth Factor Receptor 1 (FGFR1))

Andere Bezeichnung: FGFR1

Hintergrund: FGFR1 (fibroblast growth factor receptor 1) is a member of the fibroblast growth factor receptor family and contains an Ig-like domain and a tyrosine kinase domain. This receptor has multiple isoforms and is a Type I membrane protein. FGFR1 is widely expressed, with distinct isoforms expressed in specific tissues. FGFR1 binds fibroblast growth factor and induces mitogenesis and cellular differentiation. Defects in FGFR1 result in Pfeiffer syndrome associated with craniosynostosis. FGFR1 can be modified by phosphorylation and can bind basic/acidic fibroblast factor depending on the receptor isoform. FGFR1 has been shown to interact with N-cadherin and NCAM. Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)], FGFR2 [bek (bacterial expressed kinase gene product)], FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF's binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1.Synonyms: BFGFR, Basic fibroblast growth factor receptor 1, CEK, FGFBR, FLG, FLT-2, FLT2, Fibroblast growth factor receptor 1, Fms-like tyrosine kinase 2, HBGFR, N-sam, Proto-oncogene c-Fgr, bFGF-R-1

Gen-ID: 2260, 9606

UniProt: P11362

Pathways: RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Sensory Perception of Sound, Stem Cell Maintenance, S100 Proteine